AVBP Q2 2024 Earnings — ArriVent BioPharma, Inc. Common Stock Revenue & Financial Results | Market Cap Arena

AVBPArriVent BioPharma, Inc. Common Stock

$1B

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$26M

Net Income

-$22M

EPS (Diluted)

$-0.65

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$19M

Free Cash Flow

-$19M

Stock-Based Comp.

$765,000

Balance Sheet

Total Assets

$309M

Total Liabilities

$12M

Stockholders' Equity

$297M

Cash & Equivalents

$299M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$26M	-$23M	-13.8%
Net Income	-$22M	-$22M	-1.4%